Study guide
16.1 Cough, Cold & Allergic Rhinitis
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
16.1 Cough, Cold & Allergic Rhinitis
Key Takeaways Explain This Topic AI
OTC cough and cold products should NOT be used in children under 2 years; honey (≥1 year) is the preferred non-pharmacologic cough soothe, and codeine/dextromethorphan are avoided in young children.
Pseudoephedrine is contraindicated/cautioned in hypertension, ischemic heart disease, BPH with urinary retention, angle-closure glaucoma, and within 14 days of an MAOI.
Dextromethorphan is an antitussive (suppresses cough); guaifenesin is an expectorant (loosens secretions) — choose based on whether the cough is dry or productive.
Non-sedating antihistamines (cetirizine, loratadine, fexofenadine) are first-line for allergic rhinitis; intranasal corticosteroids (fluticasone, budesonide) are the most effective single therapy for moderate-to-persistent symptoms.
Sedating antihistamines such as chlorphenamine cause marked drowsiness and impair driving — counsel patients accordingly.
Last updated: August 2026
Cough and Cold: Drug or Honey First?
The common cold is viral and self-limiting; pharmacists counsel on supportive care and screen for conditions needing referral. Cough is classified as dry/non-productive (antitussive appropriate) or productive/chesty (expectorant or simply hydration).
Antitussive — dextromethorphan : suppresses the cough reflex in the medulla. Used for dry, tickling cough that disturbs sleep. Avoid in children under 2 (and many regulators advise against OTC cough/cold preparations under 6 years).
Expectorant — guaifenesin : reduces sputum viscosity so secretions clear more easily. For productive cough; encourage fluid intake alongside.
Honey : evidence-supported cough soothe. Contraindicated in infants under 1 year because of infant botulism risk. Give 1–2 teaspoons at bedtime to children ≥1 year and adults.
Paediatric safety rule
Do not recommend OTC cough/cold combination products for children under 2 years . Codeine is contraindicated for cough/pain in children under 12 and is avoided in adolescents 12–18 who are obese or have conditions that increase codeine sensitivity. Dextromethorphan is also avoided in young children because of the misuse/sedation risk.
Decongestants: Pseudoephedrine Cautions
Pseudoephedrine is a sympathomimetic that constricts nasal vasculature, easing congestion. It also raises blood pressure and heart rate. Caution/avoid in:
- Condition Reason
- Hypertension Increases BP, may antagonise antihypertensives
- Ischaemic heart disease / arrhythmia Sympathetic stimulation
- BPH with urinary retention α-agonist effect tightens bladder neck
- Angle-closure glaucoma Mydriasis may precipitate acute attack
- MAOI within 14 days Hypertensive crisis
Topical decongestants ( xylometazoline, oxymetazoline ) avoid systemic cardiovascular effects but must be limited to ≤5 days to prevent rhinitis medicamentosa (rebound congestion).
Allergic Rhinitis
Allergic rhinitis (hay fever) presents with sneezing, itchy nose/eyes, rhinorrhoea and nasal blockage. The pharmacist distinguishes intermittent vs persistent and mild vs moderate-severe (sleep disturbance, impairment of daily activities).
Stepwise approach:
Non-sedating oral antihistamine — first-line for mild intermittent disease. Cetirizine 10 mg once daily, loratadine 10 mg once daily, or fexofenadine 120–180 mg once daily. Onset within 1–3 hours; effective for sneeze/itch/rhinorrhoea, less so for congestion.
Intranasal corticosteroid — fluticasone or budesonide , one spray each nostril daily. The most effective single therapy for moderate-to-persistent rhinitis; onset over several hours to days, counsel on regular daily use (not PRN) and technique (aim away from septum to avoid epistaxis).
Sedating antihistamines (e.g. chlorphenamine 4 mg every 4–6 h ) — useful at night if sleep disrupted, but cause marked drowsiness and impair driving/machinery the next morning. Warn the patient.
Intranasal sodium cromoglicate — mild disease, paediatric preference, slow onset.
Exam traps
"Sedating antihistamines are better for daytime work" — false ; they impair performance.
Intranasal corticosteroids need regular daily use ; ordering them "as needed" reduces efficacy.
Topical decongestant beyond 5 days causes rebound congestion.
Referral red flags
Refer immediately if any of: stridor/breathing difficulty, high fever with rash, symptoms beyond 10 days or worsening after initial improvement (bacterial sinusitis suspicion), unilateral facial pain with purulent discharge, chest pain, or cough lasting >3 weeks.
Worked example — allergic rhinitis selection
A 30-year-old presents with sneezing, itchy eyes and nasal blockage every morning for the past 6 weeks, interfering with work. She takes the combined oral contraceptive pill and has no asthma. This is persistent moderate allergic rhinitis (symptoms >4 days/week and >4 consecutive weeks, with impairment). First-line is a non-sedating oral antihistamine (loratadine 10 mg daily) for immediate relief, plus an intranasal corticosteroid (fluticasone 50 µg, one spray each nostril once daily) because she has persistent blockage. Counsel her that the intranasal spray takes several days for full effect, to use it every day rather than only on bad days, to angle the nozzle away from the nasal septum, and to expect benefit within 1–2 weeks. If symptoms remain uncontrolled at 2–4 weeks, refer for prescription add-on therapy (e.g. intranasal antihistamine azelastine, or referral to exclude structural causes).
Worked example — decongestant caution
A 58-year-old man with hypertension (on amlodipine) and BPH asks for a decongestant for a heavy cold. Oral pseudoephedrine is inappropriate (hypertension, BPH with retention risk). Offer xylometazoline 0.1% nasal spray , one spray per nostril every 8–10 hours for a maximum of 5 days , plus saline nasal spray for ongoing moisture. Counsel on the rebound-congestion risk if he exceeds 5 days, and refer if facial pain or purulent discharge develops.
Antihistamine dosing table
- Drug Adult dose Key counselling
- Cetirizine 10 mg Once daily Mild somnolence in some patients; renal dose adjustment
- Loratadine 10 mg Once daily Truly non-sedating for most; hepatic dose adjustment
- Fexofenadine 120–180 mg Once daily Take with water; avoid with fruit juice (reduces absorption)
- Chlorphenamine 4 mg Every 4–6 h, max 24 mg/day Marked sedation; warn about driving and alcohol
- Key exam traps
"Topical decongestants are safe for long-term use" — false ; limit to 5 days.
"Sedating antihistamines are the first-line for daytime allergic rhinitis" — false ; non-sedating agents are first-line.
Codeine and dextromethorphan are not recommended in young children.
Pseudoephedrine is still unsafe for 14 days after stopping an MAOI, not just while the patient is taking it.